Rocket Lab's stock fell 30% after a planned insider sell-off. The distribution phase is now over, signaling a potential stealth re-accumulation by smart money.

Novavax is undervalued. It holds $751M cash, has profitable licensing deals for its Matrix-M tech, and faces activist pressure to unlock shareholder value. The market ignores this shift.

OKUR's stock trades at a negative enterprise value after a $150M private placement. Investors buy the company's IP and cash for less than the cash itself, a deep-value anomaly.

CAI stock is down 50% despite 97% revenue growth. The plunge is a market illusion, with dark pool data showing heavy institutional accumulation, not a fundamental failure.

Zai Lab (ZLAB) crashed to $16.30 in early 2026 due to forced institutional selling. However, sharp hedge fund RA Capital bought a 5.2% stake at the bottom, signaling a major accumulation event hidden in dark pool data.

Alumis's stock surge is a cynical liquidity event. Insiders bought low, hyped Phase 3 data, then sold shares high in a $345M offering. Despite cash, the drug faces a crowded market and massive cash burn.

Robinhood stock crashed 55% despite strong fundamentals, as insiders sold millions of shares at peak prices. Now, extreme off-exchange trading signals suggest major institutional accumulation at the $68 level.

Centene's $6.7B non-cash impairment triggered a sell-off, but the firm has $17B cash. Sophisticated funds are buying as insiders align for a major stock price recovery.

LUNR is a mispriced, gov-backed space infrastructure play. Its revenue is set to quintuple in 2026. High short interest and a tiny, locked-up float create a massive squeeze potential.

Lululemon's stock is down 44% despite strong cash flow & 60% margins. The market overreacted to a US slowdown, ignoring international growth & a $1B buyback. Activist pressure from founder Chip Wilson could unlock value.

Target Hospitality (TH) pivots from oil to AI infrastructure, securing a $550M+ contract to house data center workers, driving a major stock surge.

Vor Biopharma executed a reverse split, insider selling, and major capital raises. This crushed the stock price but secured $450M cash, resetting the company for institutional investors.

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.

Wave Life Sciences' stock crashed 50% on obesity drug data. But the drug targets toxic fat & preserves muscle, unlike GLP-1s. Insiders are buying, seeing a misunderstood RNA editing pioneer, not a failure.

Smart money orchestrated a VOR Biopharma sell-off, then bought back shares at a 60% discount via a PIPE, recapitalizing the company. Retail was washed out.

Aeluma's high short interest is a trap. The company has a strong cash position, and recent insider selling represents a cap table rotation, not a failing business. Bears are misreading the data.

Ciena's stock soared 500% on AI hype, but its 440x P/E ratio and exhausted short squeeze signal a dangerous bubble primed for a sharp correction.

Cheesecake Factory's revenue growth masks a 2.2% same-store sales decline. It's funding dividends and buybacks with new debt while insiders sell, signaling deep financial trouble.

Halozyme's stock drop is misunderstood. The "institutional selling" is an accounting change, not a real exit. Insider sales are pre-planned for taxes. The CEO's new pay package requires the stock to hit $115 to fully vest, showing strong board confidence.

Madrigal Pharmaceuticals (MDGL) is poised for a major short squeeze. With 24% of shares short, bears are misreading the data. The company has neutralized the GLP-1 threat via a licensing deal, extended key patents to 2045, and is hitting revenue milestones.